Treatment of Generalized Eruptive Keratoakantoma Using Acitretin Dosage

Authors

  • Molochkov Anton Vladimirovich Department of Dermatology and Venereology Faculty of Training for Medical Professionals Peoples' Friendship University of Russia, Moscow
  • Molochkova Yulia Vladimirovna Department of Dermato-venerology and Dermatologic Oncology,Moscow Regional Clinical Research Institute, Moscow
  • Medzhidova Surat Magomedovna Department of Dermato-venerology and Dermatologic Oncology,Moscow Regional Clinical Research Institute, Moscow

DOI:

https://doi.org/10.37591/rrjoi.v9i1.1538

Abstract

Keratoakantoma (KA) is a squamous neoplasia, variant of squamous cell skin cancer. In typical cases it is found to be solitary, filled with keratin, dome-shaped craterform papule with a diameter of 1–2 cm. KA regresses spontaneously within 3 months after the onset of the disease. Atypical KA persist, rarely regress spontaneously and can be giant, multinodular, centrifugum marginatum, subungual, as well as multiple, including Generalized Eruptive Keratoakantoma (GEKA). In the present study, out of the 256 patients diagnosed with KA, the GEKA was diagnosed only in two cases. In the first case, an 82-year-old patient, Acitretin was administered and a pronounced clinical effect was observed. Acitretin was prescribed in dose 25 mg once a day for 3 months. After 1 month the itching disappeared and after 3 months, there was a complete regress of the eruption.

 

Keywords: GEKA, Acitretin, Keratoakantoma

Cite this Article

Molochkov Anton Vladimirovich, Molochkova Yulia Vladimirovna, Medzhidova Surat Magomedovna. Treatment of Generalized Eruptive Keratoakantoma Using Acitretin Dosage. Research & Reviews: A Journal of Immunology. 2019; 9(1): 27–32p.

Downloads

Published

2019-05-24

Issue

Vol. 9 No. 1 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.